NCT07036003

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR): a Pilot, Randomized Placebo-controlled Trial

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Dr. David Wasserstein · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to see if people with knee osteoarthritis would be willing to comply and adhere to incorporating Recombinant Human Growth Hormone (rHGH), specifically Saizen Somatropin solution, into their treatment plan. Participants will be asked to: * Self-inject the treatment solution (placebo or somatropin) into the abdominal or gluteal area once per day for a total of 6 weeks. * Complete questionnaires related to their knee pain and activities of daily living. * Provide blood tests. * Complete various measurements including: circumference of thigh, calf, and abdomen; strength of thigh and knee; range of motion of both knees; and gait analysis.

Conditions

• Knee Osteoarthritis (Knee OA)
• Knee Osteoarthritis (OA)

Interventions

Type	Name	Description
DRUG	Somatropin (recombinant human growth hormone)	Study participants will deliver Somatropin via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks at a dose of 0.5mg/day per body surface area (0.5mg/m2/day).
DRUG	bacteriostatic saline placebo	Study participants will deliver bacteriostatic saline via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks in an identical delivery device to the experimental arm.

Timeline

• Start date: 2025-10-31
• Primary completion: 2028-07-01
• Completion: 2029-01-01
• First posted: 2025-06-25
• Last updated: 2026-03-16

Locations

1 site across 1 country: Canada